Biostar Capital
SEC exempt reporting adviser (venture capital exemption).
- HQ
- MI
BioStar Capital is a uniquely structured venture capital firm focused on transformative medical technologies. Its portfolio includes Amplitude Vascular Systems, developer of the Pulse IVL platform, which has been acquired by Stryker. Other companies include Field Medical with its FieldForce pulsed field ablation platform, Versa Vascular for tricuspid valve repair, REVA Medical with its bioresorbable scaffold, Nectero Therapeutics for abdominal aortic aneurysms, and Foldax with TRIA polymer heart valves. Louis Cannon, MD is a founder of the firm.
New fund likely raising soon
The firm's newest fund is 4 to 7 years past its first sale and no newer Form D has been filed.
01 · Says / Does
| Tag | Says | Does |
|---|---|---|
| Stages | Seed, Series A, Growth | Not enough dated deals |
| Sectors | Medical devices, Robotics | Not enough dated deals |
| Regions | Not stated | Not enough dated deals |
Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.
02 · Fund history
| Fund | Year | Size | Status |
|---|---|---|---|
| BioStar Ventures V-A, L.P. BioStar Capital is a venture capital firm focused on transformative medical technologies, with an emphasis on cardiovascular and orthopedic devices, robotics, and smart devices that address unmet patient needs. Inferred from the firm's website | 2021 | $10.2M to $16.08M (Form D and SEC adviser filing) | Late investment period |
| BioStar Ventures V, L.P. BioStar Capital is a venture capital firm focused on transformative medical technologies, with an emphasis on cardiovascular and orthopedic devices, robotics, and smart devices that address unmet patient needs. Inferred from the firm's website | 2021 | $78.54M to $105.83M (Form D and SEC adviser filing) | Late investment period |
03 · People across funds
- Louis BioStar Ventures V, L.L.C., "General Partner of the Issuer (the ""General Partner"")"
BioStar Ventures V-A, L.P. (Named on Form D)
- Louis Cannon, Senior Managing Director of the General Partner
BioStar Ventures V-A, L.P. (Named on Form D); BioStar Ventures V, L.P. (Named on Form D)
- Alan Davis, MD, Managing Director
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
- Ben Cannon, Growth Equity, Partner & Advisor
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
- Jason Johnson, CFO
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
- Jeremy Touroo, Director
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
- Louis Cannon, MD, Founder, Senior Managing Director
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
- Mark Toland, Managing Director
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
- Steven Yakubov, MD, Director
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
- William H. (Hank) Kucheman, Managing Director
BioStar Ventures V-A, L.P. (Team); BioStar Ventures V, L.P. (Team)
04 · Recent deals
No dated deals found yet.
05 · Latest from the firm
No news from the firm's website yet.
06 · Sources
- https://www.biostarcapital.com/contact
- https://www.biostarcapital.com/team
- https://www.biostarcapital.com/news
- https://www.biostarcapital.com/
- https://www.biostarcapital.com/about
Fund dates and sizes are from SEC Form D filings.
Last verified: Oct 28, 2026